Fig. 2.

Kaplan–Meier estimates for progression-free (a) and overall survival (b) of the study population. The entire cohort comprised 33 patients receiving the combination therapy with n = 28 for ipilimumab and n = 5 for PD-1 inhibition with either pembrolizumab (n = 3) or nivolumab (n = 2). The median time to disease progression was 2.5 months (2 months for ipilimumab, 5 months for PD-1; p = 0.77). The median OS was 15 months (not reached for ipilimumab, 15 months for PD-1; p = 0.98)